What the current Ozempic label reports
In the 2-year trial described by the label, diabetic retinopathy complications occurred in 3.0% of Ozempic-treated participants and 1.8% of placebo-treated participants. The label separates results by whether diabetic retinopathy was known at baseline. [1]
| Trial group | Ozempic | Placebo |
|---|---|---|
| All participants | 3.0% | 1.8% |
| Known diabetic retinopathy at baseline | 8.2% | 5.2% |
| No known diabetic retinopathy at baseline | 0.7% | 0.4% |
These percentages describe the studied population and do not predict an individual outcome. [1]
What SUSTAIN 6 did—and did not—establish
SUSTAIN 6 included 3,297 adults with advanced type 2 diabetes and high cardiovascular risk. Adjudicated diabetic retinopathy complications occurred in 50 participants receiving semaglutide (3.0%) and 29 receiving placebo (1.8%), corresponding to a hazard ratio of 1.76 with a 95% confidence interval of 1.11–2.78. [2]
The published analysis was post hoc. Its authors concluded that the majority of the observed effect may be attributable to the magnitude and rapidity of HbA1c reduction during the first 16 weeks among participants with pre-existing diabetic retinopathy, poor baseline glycemic control, and insulin treatment. [2]
Why “rapid improvement” needs careful wording
What the label says
Rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy. The label also says the effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. [1]
A symptom log is not an eye exam
Diabetic retinopathy affects blood vessels in the retina in people with diabetes. Early stages can have no symptoms; later symptoms can include blurry vision and floating spots. Diagnosis uses a dilated eye exam. [3]
A dated log can help preserve what happened and when, but it cannot screen the retina, diagnose diabetic retinopathy, or replace a dilated eye exam. Decisions about evaluation and urgency belong with the relevant clinicians. [3]
A neutral prescriber and eye-clinician handoff record
The useful record preserves dates and exact wording without assigning cause or interpreting results:
Record the exact name.
Record plan and change dates as documented.
Copy result dates and values without interpretation.
Use only what is known from clinical records.
Record dates and findings exactly as documented.
Record the date and a plain-language description.
What not to infer
The SUSTAIN 6 signal does not prove that diabetic retinopathy complications are a class-wide GLP-1 effect. [2]
The post-hoc explanation does not prove that rapid HbA1c reduction caused the trial result. [2]
The trial percentages do not predict what will happen to one person. [1]
No symptoms does not rule out early diabetic retinopathy. [3]
Questions to bring to the care team
- What does my existing eye record say about prior diabetic retinopathy?
- How does the Ozempic label’s monitoring language apply to my documented history?
- Which HbA1c dates and values are useful for you to see together?
- Which vision changes would alter the clinician’s preferred timing or urgency?
Keep the handoff legible
Put the clinician-directed plan and timeline in one record
Jabbit can keep clinician-directed schedules, reminders, history, and progress timing together. It cannot interpret HbA1c, screen the retina, diagnose diabetic retinopathy, or choose treatment.
Track your clinician-directed plan in JabbitFrequently asked questions
Do GLP-1 medicines cause diabetic retinopathy complications?
The evidence discussed here is semaglutide-specific and does not prove a class-wide effect. The current Ozempic label reports more diabetic retinopathy complications with Ozempic than placebo in one 2-year trial of adults with type 2 diabetes and high cardiovascular risk. [1]
What did the Ozempic trial report?
Complications occurred in 3.0% of Ozempic-treated participants and 1.8% of placebo-treated participants. The absolute difference was larger among participants with known diabetic retinopathy at baseline. [1]
Did rapid HbA1c improvement cause the observed complications?
That has not been proven. The published post-hoc analysis says the majority of the effect may be attributable to the magnitude and rapidity of HbA1c reduction in the first 16 weeks among a specific higher-risk subgroup. “May” and “post hoc” are essential boundaries. [2]
Can a symptom log screen for diabetic retinopathy?
No. Early diabetic retinopathy can have no symptoms, and diagnosis uses a dilated eye exam. A log can preserve dates and descriptions, but it cannot screen, diagnose, or replace the exam. [3]
Sources opened and checked
- [1]Current Ozempic prescribing information, DailyMed, revised May 2026.
- [2]Vilsbøll et al., “Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy,” Diabetes, Obesity and Metabolism, 2018; PMCID PMC5888154; DOI 10.1111/dom.13172.
- [3]National Eye Institute, Diabetic Retinopathy.
All three sources were opened and checked on August 24, 2026.